337 Expansion of Dendritic Cells Using FLT3 Ligand to Treat Glioblastoma: A Preclinical Study

Tomas Garzon-Muvdi, Antonella Mangraviti, Debebe Theodros, Eileen Kim, Michael Jay Yellin, Henry Marsh, Michael Lim

Research output: Contribution to journalArticle

Abstract

CONCLUSION: The present work suggests that an increase in antigen presentation by enhancing and recruiting dendritic cells into the brain and brain tumor may be beneficial and a potential therapeutic strategy for patients with GBM. The mechanism of this phenomenon is currently under investigation, but includes increased secretion of interferon gamma. Additionally, increased antigen presentation may aid the immune system mount a significant antitumor immune response. Further experiments evaluating the proportion of T cells that have been exposed to antigen are currently underway.

INTRODUCTION: FLT3L induces expansion and recruitment of plasmacytoid dendritic cells (pDCs) into the brain. By increasing antigen presentation, FLT3L agonists may enhance an immune response against glioblastoma (GBM). Previous results suggest that the antitumor response generated by FLT3 is secondary to production of interferon gamma. We studied the effect of FLT3L treatment of mice with a syngeneic GBM model.

METHODS: Under ACUC approval, 32 mice underwent implantation of 130 000 GL261 cells in the left striatum using a stereotactic frame. The presence of tumor was confirmed by bioluminescence imaging at day 7. Mice were randomly assigned to 4 groups: Control, FLT3 (courtesy of Celldex) treatment, Poly IC treatment, and FLT3+Poly IC treatment. Survival was assessed using log-rank analysis and described using Kaplan-Meier curves.

RESULTS: A survival experiment demonstrated that FLT3L treatment of mice resulted in 50% long-term survival of mice and improved survival compared with control groups (P = .001). Addition of Poly IC (TLR3 agonist), did not add survival benefit.

Original languageEnglish (US)
Pages (from-to)198-199
Number of pages2
JournalNeurosurgery
Volume63
DOIs
StatePublished - Aug 1 2016
Externally publishedYes

Fingerprint

Glioblastoma
Dendritic Cells
Ligands
Antigen Presentation
Survival
Interferon-gamma
Therapeutics
Control Groups
Brain
Brain Neoplasms
Immune System
T-Lymphocytes
Antigens
Neoplasms

ASJC Scopus subject areas

  • Surgery
  • Clinical Neurology

Cite this

337 Expansion of Dendritic Cells Using FLT3 Ligand to Treat Glioblastoma : A Preclinical Study. / Garzon-Muvdi, Tomas; Mangraviti, Antonella; Theodros, Debebe; Kim, Eileen; Yellin, Michael Jay; Marsh, Henry; Lim, Michael.

In: Neurosurgery, Vol. 63, 01.08.2016, p. 198-199.

Research output: Contribution to journalArticle

Garzon-Muvdi, Tomas ; Mangraviti, Antonella ; Theodros, Debebe ; Kim, Eileen ; Yellin, Michael Jay ; Marsh, Henry ; Lim, Michael. / 337 Expansion of Dendritic Cells Using FLT3 Ligand to Treat Glioblastoma : A Preclinical Study. In: Neurosurgery. 2016 ; Vol. 63. pp. 198-199.
@article{74f1b5e9037c4664b5df757dbef5ecc8,
title = "337 Expansion of Dendritic Cells Using FLT3 Ligand to Treat Glioblastoma: A Preclinical Study",
abstract = "CONCLUSION: The present work suggests that an increase in antigen presentation by enhancing and recruiting dendritic cells into the brain and brain tumor may be beneficial and a potential therapeutic strategy for patients with GBM. The mechanism of this phenomenon is currently under investigation, but includes increased secretion of interferon gamma. Additionally, increased antigen presentation may aid the immune system mount a significant antitumor immune response. Further experiments evaluating the proportion of T cells that have been exposed to antigen are currently underway.INTRODUCTION: FLT3L induces expansion and recruitment of plasmacytoid dendritic cells (pDCs) into the brain. By increasing antigen presentation, FLT3L agonists may enhance an immune response against glioblastoma (GBM). Previous results suggest that the antitumor response generated by FLT3 is secondary to production of interferon gamma. We studied the effect of FLT3L treatment of mice with a syngeneic GBM model.METHODS: Under ACUC approval, 32 mice underwent implantation of 130 000 GL261 cells in the left striatum using a stereotactic frame. The presence of tumor was confirmed by bioluminescence imaging at day 7. Mice were randomly assigned to 4 groups: Control, FLT3 (courtesy of Celldex) treatment, Poly IC treatment, and FLT3+Poly IC treatment. Survival was assessed using log-rank analysis and described using Kaplan-Meier curves.RESULTS: A survival experiment demonstrated that FLT3L treatment of mice resulted in 50{\%} long-term survival of mice and improved survival compared with control groups (P = .001). Addition of Poly IC (TLR3 agonist), did not add survival benefit.",
author = "Tomas Garzon-Muvdi and Antonella Mangraviti and Debebe Theodros and Eileen Kim and Yellin, {Michael Jay} and Henry Marsh and Michael Lim",
year = "2016",
month = "8",
day = "1",
doi = "10.1227/01.neu.0000489826.92509.76",
language = "English (US)",
volume = "63",
pages = "198--199",
journal = "Neurosurgery",
issn = "0148-396X",
publisher = "Lippincott Williams and Wilkins Ltd.",

}

TY - JOUR

T1 - 337 Expansion of Dendritic Cells Using FLT3 Ligand to Treat Glioblastoma

T2 - A Preclinical Study

AU - Garzon-Muvdi, Tomas

AU - Mangraviti, Antonella

AU - Theodros, Debebe

AU - Kim, Eileen

AU - Yellin, Michael Jay

AU - Marsh, Henry

AU - Lim, Michael

PY - 2016/8/1

Y1 - 2016/8/1

N2 - CONCLUSION: The present work suggests that an increase in antigen presentation by enhancing and recruiting dendritic cells into the brain and brain tumor may be beneficial and a potential therapeutic strategy for patients with GBM. The mechanism of this phenomenon is currently under investigation, but includes increased secretion of interferon gamma. Additionally, increased antigen presentation may aid the immune system mount a significant antitumor immune response. Further experiments evaluating the proportion of T cells that have been exposed to antigen are currently underway.INTRODUCTION: FLT3L induces expansion and recruitment of plasmacytoid dendritic cells (pDCs) into the brain. By increasing antigen presentation, FLT3L agonists may enhance an immune response against glioblastoma (GBM). Previous results suggest that the antitumor response generated by FLT3 is secondary to production of interferon gamma. We studied the effect of FLT3L treatment of mice with a syngeneic GBM model.METHODS: Under ACUC approval, 32 mice underwent implantation of 130 000 GL261 cells in the left striatum using a stereotactic frame. The presence of tumor was confirmed by bioluminescence imaging at day 7. Mice were randomly assigned to 4 groups: Control, FLT3 (courtesy of Celldex) treatment, Poly IC treatment, and FLT3+Poly IC treatment. Survival was assessed using log-rank analysis and described using Kaplan-Meier curves.RESULTS: A survival experiment demonstrated that FLT3L treatment of mice resulted in 50% long-term survival of mice and improved survival compared with control groups (P = .001). Addition of Poly IC (TLR3 agonist), did not add survival benefit.

AB - CONCLUSION: The present work suggests that an increase in antigen presentation by enhancing and recruiting dendritic cells into the brain and brain tumor may be beneficial and a potential therapeutic strategy for patients with GBM. The mechanism of this phenomenon is currently under investigation, but includes increased secretion of interferon gamma. Additionally, increased antigen presentation may aid the immune system mount a significant antitumor immune response. Further experiments evaluating the proportion of T cells that have been exposed to antigen are currently underway.INTRODUCTION: FLT3L induces expansion and recruitment of plasmacytoid dendritic cells (pDCs) into the brain. By increasing antigen presentation, FLT3L agonists may enhance an immune response against glioblastoma (GBM). Previous results suggest that the antitumor response generated by FLT3 is secondary to production of interferon gamma. We studied the effect of FLT3L treatment of mice with a syngeneic GBM model.METHODS: Under ACUC approval, 32 mice underwent implantation of 130 000 GL261 cells in the left striatum using a stereotactic frame. The presence of tumor was confirmed by bioluminescence imaging at day 7. Mice were randomly assigned to 4 groups: Control, FLT3 (courtesy of Celldex) treatment, Poly IC treatment, and FLT3+Poly IC treatment. Survival was assessed using log-rank analysis and described using Kaplan-Meier curves.RESULTS: A survival experiment demonstrated that FLT3L treatment of mice resulted in 50% long-term survival of mice and improved survival compared with control groups (P = .001). Addition of Poly IC (TLR3 agonist), did not add survival benefit.

UR - http://www.scopus.com/inward/record.url?scp=85031936935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031936935&partnerID=8YFLogxK

U2 - 10.1227/01.neu.0000489826.92509.76

DO - 10.1227/01.neu.0000489826.92509.76

M3 - Article

C2 - 27399535

AN - SCOPUS:85031936935

VL - 63

SP - 198

EP - 199

JO - Neurosurgery

JF - Neurosurgery

SN - 0148-396X

ER -